Tech Company Financing Transactions
Heptares Therapeutics Funding Round
Clarus, Stanley Family Foundation and Takeda Ventures invested in a $21 million Series B capital raise for Heptares Therapeutics. The round was announced on 6/28/2013.
Transaction Overview
Company Name
Announced On
6/28/2013
Transaction Type
Venture Equity
Amount
$21,000,000
Round
Series B
Proceeds Purpose
The company will use the financing to advance a clinical pipeline of novel drugs directed towards clinically validated targets for the treatment of neurological and psychiatric diseases.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
Bio Park Broadwater Road
Welwyn Garden City Hertfordshire, AL7 3AX
UK
Welwyn Garden City Hertfordshire, AL7 3AX
UK
Phone
Website
Email Address
Overview
Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Malcolm Weir
Chief Medical Officer
Tim Tasker
Chief Scientific Officer
Fiona Marshall
President
Daniel Grau
Browse more venture capital transactions:
Prev: 6/28/2013: Ticket Evolution venture capital transaction
Next: 6/28/2013: PaperKarma venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs